메뉴 건너뛰기




Volumn 16, Issue 6, 2018, Pages 1028-1039

Use of direct oral anticoagulants in antiphospholipid syndrome

Author keywords

antiphospholipid syndrome; direct oral anticoagulants; ischemic stroke; thrombin generation; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; RIVAROXABAN; THROMBOPLASTIN; WARFARIN; BIOLOGICAL MARKER; PHOSPHOLIPID ANTIBODY;

EID: 85047796964     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14017     Document Type: Review
Times cited : (38)

References (98)
  • 3
    • 0033834033 scopus 로고    scopus 로고
    • Epidemiology of the antiphospholipid antibody syndrome
    • Accessed May 8, 2018. Accessed April 29, 2018
    • Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 145–51. http://acrabstracts.org/abstract/systemic-lupus-erythematosus-detailed-anatomy-of-a-cohort-follow-up-for-more-than-35-years/. Accessed May 8, 2018. Accessed April 29, 2018.
    • (2000) J Autoimmun , vol.15 , pp. 145-151
    • Petri, M.1
  • 4
    • 85047786536 scopus 로고    scopus 로고
    • Systemic lupus erythematosus: detailed anatomy of a cohort (follow-up for more than 35 years)
    • [abstract]., Accessed May 10, 2018
    • Del Carmelo Gracio Tello B, Jones A, Raine C, Isenberg D. Systemic lupus erythematosus: detailed anatomy of a cohort (follow-up for more than 35 years). [abstract]. Arthritis Rheum 2016; 68(Suppl. 10). http://acrabstracts.org/abstract/systemic-lupus-erythematosus-detailed-anatomy-of-a-cohort-follow-up-for-more-than-35-years/. Accessed May 10, 2018.
    • (2016) Arthritis Rheum , vol.68
    • Del Carmelo Gracio Tello, B.1    Jones, A.2    Raine, C.3    Isenberg, D.4
  • 6
    • 0346688744 scopus 로고    scopus 로고
    • High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus
    • Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77–82.
    • (2004) Arch Intern Med , vol.164 , pp. 77-82
    • Ruiz-Irastorza, G.1    Egurbide, M.V.2    Ugalde, J.3    Aguirre, C.4
  • 8
    • 77952118055 scopus 로고    scopus 로고
    • Accessed 15 February 2018
    • Pradaxa 150 mg hard capsules. Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/medicine/24839 Accessed 15 February 2018.
    • Summary of Product Characteristics.
  • 9
    • 85047837801 scopus 로고    scopus 로고
    • Accessed 15 February 2018
    • Eliquis 5 mg film 2010;coated tablets film&#x 2010;coated tablets. Summary of Product Characteristics. Available from: http://www.medicines.org.uk/emc/medicine/27220. Accessed 15 February 2018.
    • (2010) Eliquis 5 mg film, Summary of Product Characteristics
  • 10
    • 77952118055 scopus 로고    scopus 로고
    • Accessed 15 February 2018
    • Lixiana 60 mg Film&#x 2010;Coated Tablets. Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/medicine/30506. Accessed 15 February 2018.
    • (2010) Summary of Product Characteristics
  • 11
    • 77952118055 scopus 로고    scopus 로고
    • Accessed 14 February 2018
    • Xarelto 15 and 20 mg film&#x 2010;coated tablets. Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/medicine/25586. Accessed 14 February 2018.
    • (2010) Summary of Product Characteristics
  • 14
    • 37349061734 scopus 로고    scopus 로고
    • A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
    • Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57: 1487–95.
    • (2007) Arthritis Rheum , vol.57 , pp. 1487-1495
    • Ruiz-Irastorza, G.1    Hunt, B.J.2    Khamashta, M.A.3
  • 15
    • 0030924102 scopus 로고    scopus 로고
    • A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis
    • Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101–8.
    • (1997) Arch Intern Med , vol.157 , pp. 2101-2108
    • Krnic-Barrie, S.1    O'Connor, C.R.2    Looney, S.W.3    Pierangeli, S.S.4    Harris, E.N.5
  • 16
    • 0026659095 scopus 로고
    • Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
    • Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303–8.
    • (1992) Ann Intern Med , vol.117 , pp. 303-308
    • Rosove, M.H.1    Brewer, P.M.2
  • 18
    • 0031919292 scopus 로고    scopus 로고
    • Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group
    • Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332–8.
    • (1998) Am J Med , vol.104 , pp. 332-338
    • Schulman, S.1    Svenungsson, E.2    Granqvist, S.3
  • 19
    • 84858283382 scopus 로고    scopus 로고
    • Guidelines on the investigation and management of antiphospholipid syndrome
    • Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47–58.
    • (2012) Br J Haematol , vol.157 , pp. 47-58
    • Keeling, D.1    Mackie, I.2    Moore, G.W.3    Greer, I.A.4    Greaves, M.5
  • 20
    • 84897509629 scopus 로고    scopus 로고
    • Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
    • Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 2014; 123: 1794–801.
    • (2014) Blood , vol.123 , pp. 1794-1801
    • Kearon, C.1    Akl, E.A.2
  • 22
    • 79953305113 scopus 로고    scopus 로고
    • Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies
    • Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krilis S, Machin S, Pengo V, Pierangeli S, Tektonidou M, Khamashta M. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206–18.
    • (2011) Lupus , vol.20 , pp. 206-218
    • Ruiz-Irastorza, G.1    Cuadrado, M.J.2    Ruiz-Arruza, I.3    Brey, R.4    Crowther, M.5    Derksen, R.6    Erkan, D.7    Krilis, S.8    Machin, S.9    Pengo, V.10    Pierangeli, S.11    Tektonidou, M.12    Khamashta, M.13
  • 24
    • 84856809942 scopus 로고    scopus 로고
    • VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e691S–736S.
    • (2012) Chest , vol.141 , pp. e691S-736S
    • Bates, S.M.1    Greer, I.A.2    Middeldorp, S.3    Veenstra, D.L.4    Prabulos, A.M.5    Vandvik, P.O.6
  • 29
  • 31
    • 84856772158 scopus 로고    scopus 로고
    • Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    • Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S–84S.
    • (2012) Chest , vol.141 , pp. e152S-e1584S
    • Holbrook, A.1    Schulman, S.2    Witt, D.M.3    Vandvik, P.O.4    Fish, J.5    Kovacs, M.J.6    Svensson, P.J.7    Veenstra, D.L.8    Crowther, M.9    Guyatt, G.H.10
  • 32
    • 84908096712 scopus 로고    scopus 로고
    • A review of warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant
    • Crowl A, Schullo-Feulner A, Moon JY. A review of warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant. Ann Pharmacother 2014; 48: 1479–83.
    • (2014) Ann Pharmacother , vol.48 , pp. 1479-1483
    • Crowl, A.1    Schullo-Feulner, A.2    Moon, J.Y.3
  • 33
    • 0035669154 scopus 로고    scopus 로고
    • Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins
    • Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001; 115: 672–8.
    • (2001) Br J Haematol , vol.115 , pp. 672-678
    • Tripodi, A.1    Chantarangkul, V.2    Clerici, M.3    Negri, B.4    Galli, M.5    Mannucci, P.M.6
  • 34
    • 84929508119 scopus 로고    scopus 로고
    • Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome
    • Efthymiou M, Lawrie AS, Mackie I, Arachchillage D, Lane PJ, Machin S, Cohen H. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. Thromb Res 2015; 135: 1191–7.
    • (2015) Thromb Res , vol.135 , pp. 1191-1197
    • Efthymiou, M.1    Lawrie, A.S.2    Mackie, I.3    Arachchillage, D.4    Lane, P.J.5    Machin, S.6    Cohen, H.7
  • 35
    • 70350004861 scopus 로고    scopus 로고
    • Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis
    • Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–40.
    • (2009) J Thromb Haemost , vol.7 , pp. 1737-1740
    • Pengo, V.1    Tripodi, A.2    Reber, G.3
  • 37
    • 84975764094 scopus 로고    scopus 로고
    • The laboratory's 2015 perspective on direct oral anticoagulant testing
    • Gosselin RC, Adcock DM. The laboratory's 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost 2016; 14: 886–93.
    • (2016) J Thromb Haemost , vol.14 , pp. 886-893
    • Gosselin, R.C.1    Adcock, D.M.2
  • 38
    • 84929347366 scopus 로고    scopus 로고
    • Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory
    • Gosselin RC, Adcock DM. Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory. Int J Lab Hematol 2015; 37(Suppl. 1): 46–51.
    • (2015) Int J Lab Hematol , vol.37 , pp. 46-51
    • Gosselin, R.C.1    Adcock, D.M.2
  • 39
    • 85031667432 scopus 로고    scopus 로고
    • The effects of indirect- and direct-acting anticoagulants on lupus anticoagulant assays: a large, retrospective study at a Coagulation Reference Laboratory
    • Seheult JN, Meyer MP, Bontempo FA, Chibisov I. The effects of indirect- and direct-acting anticoagulants on lupus anticoagulant assays: a large, retrospective study at a Coagulation Reference Laboratory. Am J Clin Pathol 2017; 147: 632–40.
    • (2017) Am J Clin Pathol , vol.147 , pp. 632-640
    • Seheult, J.N.1    Meyer, M.P.2    Bontempo, F.A.3    Chibisov, I.4
  • 40
    • 84975499203 scopus 로고    scopus 로고
    • The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples
    • Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2016; 48: 60–71.
    • (2016) Pathology , vol.48 , pp. 60-71
    • Bonar, R.1    Favaloro, E.J.2    Mohammed, S.3    Ahuja, M.4    Pasalic, L.5    Sioufi, J.6    Marsden, K.7
  • 41
    • 84896116136 scopus 로고    scopus 로고
    • Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin
    • Martinuzzo ME, Barrera LH, D'adamo MA, Otaso JC, Gimenez MI, Oyhamburu J. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol 2014; 36: 144–50.
    • (2014) Int J Lab Hematol , vol.36 , pp. 144-150
    • Martinuzzo, M.E.1    Barrera, L.H.2    D'adamo, M.A.3    Otaso, J.C.4    Gimenez, M.I.5    Oyhamburu, J.6
  • 43
    • 80051595884 scopus 로고    scopus 로고
    • Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time
    • van Os GM, de Laat B, Kamphuisen PW, Meijers JC, De Groot PG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011; 9: 1657–9.
    • (2011) J Thromb Haemost , vol.9 , pp. 1657-1659
    • van, O.G.M.1    de, L.B.2    Kamphuisen, P.W.3    Meijers, J.C.4    De Groot, P.G.5
  • 44
    • 84928938571 scopus 로고    scopus 로고
    • False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome
    • Goralczyk T, Iwaniec T, Wypasek E, Undas A. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul Fibrinolysis 2015; 26: 473–5.
    • (2015) Blood Coagul Fibrinolysis , vol.26 , pp. 473-475
    • Goralczyk, T.1    Iwaniec, T.2    Wypasek, E.3    Undas, A.4
  • 45
    • 84872251979 scopus 로고    scopus 로고
    • Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions
    • Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013; 109: 127–36.
    • (2013) Thromb Haemost , vol.109 , pp. 127-136
    • Mani, H.1    Hesse, C.2    Stratmann, G.3    Lindhoff-Last, E.4
  • 48
    • 77949329048 scopus 로고    scopus 로고
    • Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants
    • Devreese K, Peerlinck K, Hoylaerts MF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood 2010; 115: 870–8.
    • (2010) Blood , vol.115 , pp. 870-878
    • Devreese, K.1    Peerlinck, K.2    Hoylaerts, M.F.3
  • 49
    • 60849121101 scopus 로고    scopus 로고
    • Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography
    • Devreese K, Peerlinck K, Arnout J, Hoylaerts MF. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography. Thromb Haemost 2009; 101: 185–96.
    • (2009) Thromb Haemost , vol.101 , pp. 185-196
    • Devreese, K.1    Peerlinck, K.2    Arnout, J.3    Hoylaerts, M.F.4
  • 50
    • 84921493869 scopus 로고    scopus 로고
    • Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism
    • Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res 2015; 135: 388–93.
    • (2015) Thromb Res , vol.135 , pp. 388-393
    • Arachchillage, D.R.1    Efthymiou, M.2    Mackie, I.J.3    Lawrie, A.S.4    Machin, S.J.5    Cohen, H.6
  • 51
    • 36348956128 scopus 로고    scopus 로고
    • Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants
    • Samama MM, Le FL, Guinet C, Gerotziafas G, Depasse F. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007; 5: 2554–6.
    • (2007) J Thromb Haemost , vol.5 , pp. 2554-2556
    • Samama, M.M.1    Le, F.L.2    Guinet, C.3    Gerotziafas, G.4    Depasse, F.5
  • 52
    • 34247869897 scopus 로고    scopus 로고
    • Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation
    • Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955–62.
    • (2007) J Thromb Haemost , vol.5 , pp. 955-962
    • Gerotziafas, G.T.1    Petropoulou, A.D.2    Verdy, E.3    Samama, M.M.4    Elalamy, I.5
  • 54
    • 35448932027 scopus 로고    scopus 로고
    • Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
    • Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47: 1398–407.
    • (2007) J Clin Pharmacol , vol.47 , pp. 1398-1407
    • Graff, J.1    von, H.N.2    Misselwitz, F.3    Kubitza, D.4    Becka, M.5    Breddin, H.K.6    Harder, S.7
  • 55
    • 84858335249 scopus 로고    scopus 로고
    • In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux
    • Samama MM, Mendell J, Guinet C, Le FL, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 2012; 129: e77–82.
    • (2012) Thromb Res , vol.129 , pp. e77-82
    • Samama, M.M.1    Mendell, J.2    Guinet, C.3    Le, F.L.4    Kunitada, S.5
  • 56
    • 84899721137 scopus 로고    scopus 로고
    • Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban
    • Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2014; 111: 989–95.
    • (2014) Thromb Haemost , vol.111 , pp. 989-995
    • Herrmann, R.1    Thom, J.2    Wood, A.3    Phillips, M.4    Muhammad, S.5    Baker, R.6
  • 57
    • 84954349431 scopus 로고    scopus 로고
    • An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban
    • Wan H, Yang Y, Zhu J, Wu S, Zhou Z, Huang B, Wang J, Shao X, Zhang H. An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban. Blood Coagul Fibrinolysis 2016; 27: 882–5.
    • (2016) Blood Coagul Fibrinolysis , vol.27 , pp. 882-885
    • Wan, H.1    Yang, Y.2    Zhu, J.3    Wu, S.4    Zhou, Z.5    Huang, B.6    Wang, J.7    Shao, X.8    Zhang, H.9
  • 58
    • 84929519341 scopus 로고    scopus 로고
    • How the direct oral anticoagulant apixaban affects thrombin generation parameters
    • Tripodi A, Padovan L, Veena C, Scalambrino E, Testa S, Peyvandi F. How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res 2015; 135: 1186–90.
    • (2015) Thromb Res , vol.135 , pp. 1186-1190
    • Tripodi, A.1    Padovan, L.2    Veena, C.3    Scalambrino, E.4    Testa, S.5    Peyvandi, F.6
  • 59
    • 25844525489 scopus 로고    scopus 로고
    • Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
    • Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412–21.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 412-421
    • Kubitza, D.1    Becka, M.2    Voith, B.3    Zuehlsdorf, M.4    Wensing, G.5
  • 61
    • 84887112232 scopus 로고    scopus 로고
    • Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature
    • Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, de Ramire JG, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65: 1869–73.
    • (2013) Arthritis Care Res (Hoboken) , vol.65 , pp. 1869-1873
    • Andreoli, L.1    Chighizola, C.B.2    Banzato, A.3    Pons-Estel, G.J.4    de Ramire, J.G.5    Erkan, D.6
  • 62
    • 84999269006 scopus 로고    scopus 로고
    • Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER(R), RE-COVER II, and RE-MEDY
    • Goldhaber SZ, Eriksson H, Kakkar A, Schellong S, Feuring M, Fraessdorf M, Kreuzer J, Schueler E, Schulman S. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER(R), RE-COVER II, and RE-MEDY. Vasc Med 2016; 21: 506–14.
    • (2016) Vasc Med , vol.21 , pp. 506-514
    • Goldhaber, S.Z.1    Eriksson, H.2    Kakkar, A.3    Schellong, S.4    Feuring, M.5    Fraessdorf, M.6    Kreuzer, J.7    Schueler, E.8    Schulman, S.9
  • 67
    • 84960434570 scopus 로고    scopus 로고
    • Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases
    • Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 2016; 35: 801–5.
    • (2016) Clin Rheumatol , vol.35 , pp. 801-805
    • Signorelli, F.1    Nogueira, F.2    Domingues, V.3    Mariz, H.A.4    Levy, R.A.5
  • 68
    • 84928625226 scopus 로고    scopus 로고
    • The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases
    • Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res 2015; 135: 1035–6.
    • (2015) Thromb Res , vol.135 , pp. 1035-1036
    • Son, M.1    Wypasek, E.2    Celinska-Lowenhoff, M.3    Undas, A.4
  • 69
    • 85021733216 scopus 로고    scopus 로고
    • Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
    • Resseguier AS, Pereira B, Rieu V, Le GG, Grobost V, Ruivard M. Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome? Lupus 2017; 26: 1297–303.
    • (2017) Lupus , vol.26 , pp. 1297-1303
    • Resseguier, A.S.1    Pereira, B.2    Rieu, V.3    Le, G.G.4    Grobost, V.5    Ruivard, M.6
  • 71
    • 85008414264 scopus 로고    scopus 로고
    • The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome
    • Malec K, Goralczyk T, Undas A. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb Res 2017; 152: 93–7.
    • (2017) Thromb Res , vol.152 , pp. 93-97
    • Malec, K.1    Goralczyk, T.2    Undas, A.3
  • 73
    • 84929471149 scopus 로고    scopus 로고
    • Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism
    • Sciascia S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis 2015; 26: 476–7.
    • (2015) Blood Coagul Fibrinolysis , vol.26 , pp. 476-477
    • Sciascia, S.1    Breen, K.2    Hunt, B.J.3
  • 75
    • 77950377251 scopus 로고    scopus 로고
    • Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression
    • Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010; 49: 281–8.
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 281-288
    • Mak, A.1    Cheung, M.W.2    Cheak, A.A.3    Ho, R.C.4
  • 78
    • 84876802600 scopus 로고    scopus 로고
    • Surrogate outcomes in clinical trials: a cautionary tale
    • Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 2013; 173: 611–12.
    • (2013) JAMA Intern Med , vol.173 , pp. 611-612
    • Svensson, S.1    Menkes, D.B.2    Lexchin, J.3
  • 80
    • 84991627503 scopus 로고    scopus 로고
    • Rivaroxaban to treat thrombotic antiphospholipid syndrome
    • Urbanus RT. Rivaroxaban to treat thrombotic antiphospholipid syndrome. Lancet Haematol 2016; 3: e403–4.
    • (2016) Lancet Haematol , vol.3 , pp. e403-e404
    • Urbanus, R.T.1
  • 82
    • 84959175335 scopus 로고    scopus 로고
    • Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial
    • Pengo V, Banzato A, Bison E, Zoppellaro G, Padayattil JS, Denas G. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 2016; 25: 301–6.
    • (2016) Lupus , vol.25 , pp. 301-306
    • Pengo, V.1    Banzato, A.2    Bison, E.3    Zoppellaro, G.4    Padayattil, J.S.5    Denas, G.6
  • 85
    • 84984694270 scopus 로고    scopus 로고
    • Management of rivaroxaban in relation to bodyweight and body mass index
    • Uprichard J. Management of rivaroxaban in relation to bodyweight and body mass index. Ther Adv Cardiovasc Dis 2016; 10: 294–303.
    • (2016) Ther Adv Cardiovasc Dis , vol.10 , pp. 294-303
    • Uprichard, J.1
  • 86
    • 84988517596 scopus 로고    scopus 로고
    • Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience
    • Arachchillage D, Reynolds R, Devey T, Maclean R, Kitchen S, van Veen JJ. Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience. Thromb Res 2016; 147: 32–5.
    • (2016) Thromb Res , vol.147 , pp. 32-35
    • Arachchillage, D.1    Reynolds, R.2    Devey, T.3    Maclean, R.4    Kitchen, S.5    van Veen, J.J.6
  • 89
    • 84870813335 scopus 로고    scopus 로고
    • Guideline on the management of bleeding in patients on antithrombotic agents
    • Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013; 160: 35–46.
    • (2013) Br J Haematol , vol.160 , pp. 35-46
    • Makris, M.1    Van, V.J.J.2    Tait, C.R.3    Mumford, A.D.4    Laffan, M.5
  • 92
    • 84994376738 scopus 로고    scopus 로고
    • Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature
    • Dufrost V, Risse J, Zuily S, Wahl D. Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep 2016; 18: 74.
    • (2016) Curr Rheumatol Rep , vol.18 , pp. 74
    • Dufrost, V.1    Risse, J.2    Zuily, S.3    Wahl, D.4
  • 93
    • 79960325537 scopus 로고    scopus 로고
    • Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation
    • Huq FY, Tvarkova K, Arafa A, Kadir RA. Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. Contraception 2011; 84: 128–32.
    • (2011) Contraception , vol.84 , pp. 128-132
    • Huq, F.Y.1    Tvarkova, K.2    Arafa, A.3    Kadir, R.A.4
  • 94
    • 84962573834 scopus 로고    scopus 로고
    • Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use
    • Martinelli I, Lensing AW, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016; 127: 1417–25.
    • (2016) Blood , vol.127 , pp. 1417-1425
    • Martinelli, I.1    Lensing, A.W.2    Middeldorp, S.3
  • 96
    • 84921431140 scopus 로고    scopus 로고
    • Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding
    • 2
    • Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 2: CD002126.
    • (2000) Cochrane Database Syst Rev , pp. CD002126
    • Lethaby, A.E.1    Cooke, I.2    Rees, M.3
  • 98
    • 84983288382 scopus 로고    scopus 로고
    • Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH
    • Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14: 1673–6.
    • (2016) J Thromb Haemost , vol.14 , pp. 1673-1676
    • Cohen, H.1    Arachchillage, D.R.2    Middeldorp, S.3    Beyer-Westendorf, J.4    Abdul-Kadir, R.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.